Final text for addition to The International Pharmacopoeia (June 2010)

Similar documents
ARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) ARTESUNATI COMPRESSI ARTESUNATE TABLETS

ARTENIMOLUM ARTENIMOL. Adopted revised text for addition to The International Pharmacopoeia

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)

RITONAVIRI COMPRESSI RITONAVIR TABLETS. Final text for addition to The International Pharmacopoeia (July 2012)

Revision of monograph in the 4 th Edition of The International Pharmacopoeia (August 2008)

CYCLOSERINE Proposal for revision of The International Pharmacopoeia (August 2012)

CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015)

CLINDAMYCIN PHOSPHATE (CLINDAMYCINI PHOSPHAS) REVISED DRAFT MONOGRAPH FOR INCLUSION IN The International Pharmacopoeia (August 2016)

Tenofovir disoproxil fumarate (Tenofoviri disoproxili fumaras)

ABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012)

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN THE FOURTH EDITION OF The International Pharmacopoeia

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS

Draft proposal for The International Pharmacopoeia

PROPOSAL FOR REVISION OF MONOGRAPH IN THE FOURTH EDITION OF The International Pharmacopoeia MEFLOQUINE HYDROCHLORIDE (JANUARY 2012) DRAFT FOR COMMENT

EMTRICITABINE AND TENOFOVIR TABLETS

LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT

SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010)

Change to read: BRIEFING

Methotrexate. (Ph. Eur. monograph 0560) C 20 H 22 N 8 O Action and use. Dihydrofolate reductase inhibitor; cytostatic.

Draft monograph for inclusion in. The International Pharmacopoeia. Dextromethorphani solutionum peroralum - Dextromethorphan oral solution

TENOFOVIRI DISOPROXILIS FUMARAS TENOFOVIR DISOPROXIL FUMARATE

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016.

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS

The International Pharmacopoeia TENOFOVIR DISOPROXIL FUMARATE (JULY 2012)

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS

ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006)

HEPARIN SODIUM. Heparinum natricum

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012)

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010)

REVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM. (August 2010)

BRIEFING Assay + + +

Pectins. Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016

MONOGRAPHS (NF) Pharmacopeial Forum 616 HARMONIZATION Vol. 31(2) [Mar. Apr. 2005]

BRIEFING. Nonharmonized attributes: Identification, Heavy metals, Characters, Labeling, Bacterial endotoxins, Sterility, Storage.

HEPARIN SODIUM. Heparinum natricum. PA/PH/Exp. 6/T (09) 42 PUB

19 Nosiheptide S O. For chickens (excluding broilers) For broilers. Finishing period broilers Growing period broilers. Stating chicks Growing chicks

B - Barium chloride (0.1 mol/l) VS... Butylated hydroxytoluene R

Läkemedelsverkets författningssamling

» Croscarmellose Sodium is a cross linked polymer of carboxymethylcellulose sodium.

» Monohydrate Citric Acid contains one molecule of water of hydration. It contains not less than 99.5 percent and not more than 100.

6.02 Uniformity of Dosage Units

CELLULOSE, MICROCRYSTALLINE. Cellulosum microcristallinum. Cellulose, microcrystalline EUROPEAN PHARMACOPOEIA 7.0

Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica

21 Virginiamycin OH O. For chickens (except for broilers) broilers. Added amount 5~15 5~15 10~20 10~20

E17 ETHYLCELLULOSE. Revision 3 Stage 4

BRIEFING. Pharmacopeial Discussion Group Sign Off Document Attributes EP JP USP Definition Identification B Identification C + + +

HYDROXYPROPYLCELLULOSE, LOW SUBSTITUTED Stage 4, Revision 1 CP: USP BRIEFING NOTE

Yeast Extracts containing Mannoproteins (Tentative)

Chemical Pharmaceutical Quality Control. Prof.Dr.Joumaa Al- Zehouri Damascus university Faculty of Pharmacy

CLINDAMYCIN PALMITATE

1 out of 8. Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 86th Meeting 2018 ERYTHROSINE

MONOGRAPHS (USP) Saccharin Sodium

Draft Indian Standard SODIUM HYDROXIDE, FOOD GRADE SPECIFICATION

2 Avilamycin R 1. For chickens (except for broilers) Starting chicks Growing chicks. Starting broilers. Finishing broilers

PHCH 402: Analytical Quality Control Different methods of analysis of some groups of drugs in common use in Nigeria (8 hrs)

Laboratorios CONDA, S.A. Distributed by Separations

ISOMALT. Chemical formula 6-O-alpha-D-Glucopyranosyl-D-sorbitol: C 12 H 24 O 11 1-O-alpha-D-Glucopyranosyl-D-mannitol dihydrate: C 12 H 24 O 11 2H 2 O

Title Revision n date

BRIEFING. Nonharmonized attributes: Characters, Microbial Enumeration Tests, and Tests for Specified Microorganisms, and Packing and Storage (USP)

ISOMALT. Stage 4. C 12 H 24 O 11 M r C 12 H 24 O 11, 2H 2 O M r DEFINITION

Heparin Sodium ヘパリンナトリウム

1 Zinc bacitracin or manganese bacitracin Zinc bacitracin, Manganese bacitracin

COMMON BARBERRY FOR HOMOEOPATHIC PREPARATIONS BERBERIS VULGARIS FOR HOMOEOPATHIC PREPARATIONS

The Amendment of Standards for Specification, Scope, Application and Limitation of Food Additives

Lutein Esters from Tagetes Erecta

L 346/6 Official Journal of the European Union

Amendment of Standards for Specification, Scope, Application and Limitation of Food Additives

The Draft Amendment of Standards for Specification, Scope, Application and Limitation of Food Additives

PRESCRIBING INFORMATION

--> Buy True-PDF --> Auto-delivered in 0~10 minutes. GB Translated English of Chinese Standard: GB1886.

PRESCRIBING INFORMATION PRODUCT MONOGRAPH HUMATIN*CAP

AMERICAN SPIKENARD FOR HOMOEOPATHIC PREPARATIONS ARALIA RACEMOSA FOR HOMOEOPATHIC PREPARATIONS

PRESCRIBING INFORMATION. BaciJect. Bacitracin for injection U.S.P. Powder for Solution. 50,000 Units/Vial. Antibiotic

Revision Bulletin 28 Jul Aug 2017 Chemical Medicines Monographs 3

Compliance. Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison ( or

Quetiapine Tablets. Expert Committee Monographs Chemical Medicines 4 Reason for Revision Compliance

BRIEFING. 1. Definition Changed to include only Wheat Starch, as to conform to the individual monograph for Wheat Starch.

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

Development and Validation for Simultaneous Estimation of Sitagliptin and Metformin in Pharmaceutical Dosage Form using RP-HPLC Method

22 Bicozamycin (Bicyclomycin)

SIMAROUBA CEDRON FOR HOMOEOPATHIC PREPARATIONS CEDRON FOR HOMOEOPATHIC PREPARATIONS

Purity Tests for Modified Starches

COCHINEAL FOR HOMOEOPATHIC PREPARATIONS COCCUS CACTI FOR HOMOEOPATHIC PREPARATIONS

European Pharmacopoeia solutions

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

contents of the monograph in effect today. Please refer to the current edition of the USP NF for official text.

SOUTH AFRICAN NATIONAL STANDARD

E55A GELATIN, GELLING GRADE Gelatina

ABSINTHIUM FOR HOMOEOPATHIC PREPARATIONS ABSINTHIUM FOR HOMOEOPATHIC PREPARATIONS

Student Practical Guide (1) Milk of Magnesia

Petrolatum. Stage 4, Revision 1. Petrolatum is a purified semi solid mixture of hydrocarbons obtained from petroleum.

Figure 2. Figure 1. Name: Bio AP Lab Organic Molecules

INTERNATIONAL ŒNOLOGICAL CODEX. PROTEIN PLANT ORIGIN FROM WHEAT, PEAS and POTATOES (OENO 28/2004, ) OIV-OENO OIV-OENO

This revision also necessitates a change in the table numbering in the test for Organic Impurities.

LAVENDER FOR HOMOEOPATHIC PREPARATIONS LAVANDULA VERA FOR HOMOEOPATHIC PREPARATIONS

Pharmacopeial Forum 818 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] ERRATA

Study of Phytochemical Screening and Antimicrobial Activity of Citrus aurantifolia Seed Extracts

National Standard of the People s Republic of China. National food safety standard. Determination of pantothenic acid in foods for infants and

INTERIM REVISION ANNOUNCEMENT

Transcription:

June 2010 KANAMYCIN ACID SULFATE: Final text for addition to The International Pharmacopoeia (June 2010) This monograph was adopted at the Forty-fourth WH Expert Committee on Specifications for Pharmaceutical Preparations in ctober 2009 for addition to the 4 th Edition of the International Pharmacopoeia. Chemical name. Kanamycin acid sulfate; CAS Reg. No. 64013-70-3. Description. White or almost white powder. Solubility. Freely soluble in water, practically insoluble in acetone R or ethanol (~750 g/l) TS. Category. Antibacterial. Storage. Kanamycin acid sulfate should be kept in a tightly closed container, or if sterile, in a hermetically closed container. Labelling. The label states: - the content in terms of IU per mg, calculated with reference to the dried substance, - where applicable, that the substances is free from bacterial endotoxins, - where applicable, that the substance is sterile. Additional information. Kanamycin acid sulfate is hygroscopic. Requirements Definition. Kanamycin acid sulfate is a form of kanamycin sulfate prepared by adding sulfuric acid to a solution of Kanamycin monosulfate or kanamycin and drying by a suitable method; Kanamycin acid sulfate, Kanamycin monosulfate and kanamycin are

page 2 produced by fermentation. Kanamycin acid sulfate contains not less than 670 International Units per mg, with reference to the dried substance. Manufacture. Kanamycin acid sulfate is produced by methods of manufacture designed to eliminate or minimize substances lowering blood pressure. The method of manufacture is validated to demonstrate that the product, if tested, would comply with the test as described under 3.7 Undue toxicity, using 0.5 ml of a solution containing 2 mg per ml. Identity tests Either tests A and D or tests B, C and D may be applied. A. Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R5 as the coating substance and a 0.75 M phosphate buffer ph 7.0 as the mobile phase. Prepare the 0.75 M phosphate buffer ph 7.0 by mixing 0.75 M potassium dihydrogen phosphate R with 0.75 M dipotassium dihydrogen phosphate R until ph 7.0 is reached. Apply separately to the plate 2 µl of each of the following solutions in water R. For solution (A) use 5 mg of the test substance per ml. For solution (B) use 5 mg of kanamycin monosulfate RS per ml. For solution (C) use a mixture of 5 mg of kanamycin monosulfate RS and 5 mg of neomycin sulfate RS per ml. After removing the plate from the chromatographic chamber, heat it at 110 C for 5 minutes, spray it with triketohydrindene/methanol reagent TS and heat further at 110 C for 15 minutes. The principal spot obtained with solution A corresponds in position, appearance, and intensity with that obtained with solution B. The test is not valid unless the chromatogram obtained with solution C shows two clearly separated spots. B. Dissolve 10 mg in 1 ml of water R, add 1 ml of sodium hydroxide (~80 g/l) TS and mix, then add 2 ml of cobalt(ii) nitrate (10 g/l) TS; a greyish colour with precipitate is produced.

page 3 C. Dissolve 0.05 g in 3 ml of water R and add 4 ml of anthrone TS; a bluish violet colour is produced. D. Complies with the test for Sulfate. Specific optical rotation (1.4). Use a 10 mg/ml solution and calculate with reference to 20 the dried substance; [α] C D = + 103 to + 115. Sulfated ash (2.3). After ignition moisten the residue with 2 ml of nitric acid (~1000 g/l) TS and about 0.2 ml of sulfuric acid (~1760 g/l) TS; not more than 5 mg/g. Sulfate. 0.23 0.26 g/g, calculated as S 4 with reference to the dried substance. Dissolve 0.175 g in 100 ml of water R and adjust the ph of the solution to ph 11 using ammonia (~260 g/l) TS. Add 10.0 ml of barium chloride (0.1 mol/l) VS and 0.5 mg of phthalein purple R. Titrate with disodium edetate (0.1 mol/l) VS adding 50 ml of ethanol (~750 g/l) TS when the colour of the solution begins to change and continue the titration until the violet-blue colour disappears. Each ml of barium chloride (0.1 mol/l) VS is equivalent to 9.606 mg of S 4. Loss on drying. Dry at 60 C for 3 hours under reduced pressure (not exceeding 0.6 kpa or about 5 mm mercury); it loses not more than 50 mg/g. ph value (1.13). ph of a 10 mg/ml solution in carbon-dioxide-free water R, 5.5-7.5. Bacterial endotoxins. If intended for use in the manufacture of a parenteral dosage form, carry out the test as described under 3.4 Test for bacterial endotoxins; contains not more than 0.67 IU of endotoxin per mg of kanamycin. Sterility. If intended for use in the manufacture of either a parenteral or other sterile dosage form without a further appropriate sterilization procedure, complies with 3.2.2 Sterility testing of antibiotics, applying the membrane filtration test procedure and using the sampling plan described under 3.2.1 Test for sterility of non-injectable preparations. Related substances. Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R5 as the coating substance and a 0.5 M phosphate

page 4 buffer ph 7.0 as the mobile phase. Prepare the 0.75 M phosphate buffer ph 7.0 by mixing 0.75 M potassium dihydrogen phosphate R with 0.75 M dipotassium dihydrogen phosphate R until ph 7.0 is reached. Apply separately to the plate 5 µl of each of the following solutions in water R. For solution (1) use 10 mg of the test substance per ml. For solution (2) use 0.5 mg of the test substance per ml. For solution (3) use 0.3 mg of the test substance per ml. After removing the plate from the chromatographic chamber, heat it at 110 C for 5 minutes, spray it with triketohydrindene/methanol reagent TS and heat further at 110 C for 15 minutes. For solution (4), use a mixture of 5 mg of kanamycin monosulfate RS and 5 mg of neomycin sulfate RS per ml of water R. Any spot obtained with solution (1), other than the principal spot is not more intense than that obtained with solution (2) (5.0%) and not more than one such spot is more intense than that obtained with solution (3) (3.0%). The test is not valid unless the chromatogram obtained with solution (4) shows two clearly separated spots. Assay. Carry out the assay as described under 3.1 Microbiological assay of antibiotics, using either (a) Bacillus subtilis (ATCC 6633) as the test organism, culture medium Cm1 with a final ph of 7.9, sterile phosphate buffer ph 8.0 TS1, an appropriate concentration of kanamycin acid sulfate (usually 5-20 IU per ml), and an incubation temperature of 30-37 C, or (b) Staphylococcus aureus (ATCC 6538 P) as the test organism, the same culture medium and phosphate buffer, an appropriate concentration of kanamycin acid sulfate (usually 10 IU per ml), and an incubation temperature of 35-39 C. The precision of the assay is such that the fiducial limits of error of the estimated potency (P = 0.95) are not less than 95% and not more than 105% of the estimated potency. The upper fiducial limit of error of the estimated potency (P = 0.95) is not less than 670 IU per mg, calculated with reference to the dried substance. [Note from the Secretariat: general method 3.1 will be revised in order to add a relevant entry in Table 4 for kanamycin.]

page 5 Impurities H 2 N H H H H H H A. 4--(3-amino-3-deoxy-α-D-glucopyranosyl)-6--(2,6-diamino-2,6-dideoxy-α-Dglucopyranosyl)-2-deoxy-L-streptamine (kanamycin B). *** New reagents to be added to Ph.Int. Barium chloride (0.1 mol/l) VS. Barium chloride R, dissolved in water R to contain 20.8 g of BaCl 2 in 1000 ml. Method of standardization. Ascertain the exact concentration of the solution by following the method described under barium chloride (0.5 mol/l) VS. Phthalein purple R. C 32 H 32 N 2 12. x H 2. 2,2',2'',2'''-{3-oxo-2-benzofuran-1(3H)- ylidenebis[(6-hydroxyy-5-methyl-3,1-phenylene)methylenenitrilo]}tetraacetic acid.. Description. Yellowish-white to brownish powder. Solubility. Practically insoluble in water, soluble in ethanol (~750 g/l) TS. Test for sensitivity. Dissolve 10 mg in 1 ml of ammonia (~260 g/l) TS and dilute to 100 ml with water R. To 5 ml of the solution add 95 ml of water R, 4 ml of ammonia (~260 g/l) TS, 50 ml of ethanol (~750 g/l) TS and 0.1 ml of barium chloride (0.1 mol/l) VS. The solution is blue-violet. Add 0.15 ml of disodium edetate (0.1 mol/l) VS. The solution becomes colourless. ***